

ASX Announcement

20 November 2025

ReNerve completes \$3.2m capital raising to accelerate sales & marketing

ReNerve Limited (ASX, "ReNerve" or "the Company"), is pleased to announce it has received commitments from new and existing institutional and sophisticated investors, to raise approximately \$3.2M before costs (**Placement**) via a two tranche placement of approximately 26,666,667 fully paid ordinary shares (**New Shares**) at a price of \$0.12 per share (**Offer Price**).

The Offer Price represents a 22.6% discount to the last closing price of ReNerve's shares on 17 November 2025 and a 28.2% discount to the 15-day VWAP of ReNerve's shares.

Placement Structure

The Placement comprises two tranches:

- an unconditional tranche to raise approximately \$2.6M (before costs) via the issue of approximately 21,581,587 New Shares utilising the Company's existing placement capacity pursuant to ASX Listing Rule 7.1 (**Tranche 1**).
- a conditional tranche to raise approximately \$0.6M (before costs) via the issue of 5,085,080 New Shares, subject to shareholder approval being obtained at an Extraordinary General Meeting, which is presently anticipated to be held on 5 January 2026 (**EGM**) (**Tranche 2**).

The Placement was well supported by new and existing shareholders and the Company is pleased to welcome the new investors on to the register.

"This capital raise strengthens our balance sheet and enables us to accelerate our sales and marketing efforts in the US and beyond. We now have three established product ranges generating revenue, with our fourth product line – the conduit range – launching soon to drive the next phase of growth. 2026 is shaping up to be a transformational year, with several pivotal milestones on the horizon that we believe will be material to shareholders." said **CEO Dr Julian Chick**.

The 26,666,667 New Shares are to be issued with a one for one free attaching option (**New Options**) with an exercise price of \$0.18 and a maturity date of two years from the date of issue. However, issuance of the 26,666,667 attaching New Options will be subject to shareholder approval being obtained at the EGM.

The Tranche 1 New Shares are to be issued under the Company's capacity pursuant to ASX Listing Rule 7.1 (21,581,587 New Shares) following a capacity refresh at the Company's upcoming Annual General Meeting (**AGM**) being held on 27 November 2025.



The Tranche 2 New Shares are to be issued following the Company obtaining shareholder approval at the EGM. Further details on the EGM time and venue will be provided in a notice of meeting to be despatched to shareholders shortly.

Use of Funds

Funds raised from the Placement will enable the Company to accelerate its growth and will be applied to fund:

- acceleration of the sales and marketing programmes for the Company's product lines already on market, the NervAlign® Nerve Cuff and EmpliQ ranges;
- ongoing development of new products that the Company is planning to bring to market, including its range of nerve conduit products and its nerve guide matrix product;
- strengthening of the Company's sales team; and
- working capital.

Alpine Capital Pty Ltd (Alpine) and SP Corporate Advisory Pty Ltd (Spark Plus) acted as the Joint Lead Managers to the Placement.

Timetable

Event	Indicative Date
Announcement of Placement and trading halt lifted	Thursday 20 November 2025
Settlement of New Shares under Tranche 1 of the Placement	Friday 28 November 2025
Issue of New Shares under Tranche 1 of the Placement	Monday 1 December 2025
Quotation and trading of New Shares under Tranche 1 of the Placement	Monday 1 December 2025
EGM and settlement, quotation and trading of New Shares under Tranche 2 of the Placement	Monday 5 January 2026

Note: This timetable is indicative only and is subject to change at the Company's discretion. The commencement of trading and quotation of shares under the Placement is subject to confirmation from the ASX. Subject to the requirements of the Corporations Act 2001 (Cth), the ASX Listing Rules and other applicable rules, the Company reserves the right to amend this timetable at any time, without notice.

- ENDS -

This announcement has been approved for release by the Company's Board of Directors.

For further information and enquiries, please contact:

Dr Julian Chick
CEO & Managing Director
ReNerve Ltd
+61 (03) 9482 3940
info@renerve.com.au

Matthew Wright
Investor & Media Relations
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au

About ReNerve Limited (ASX:RNV)

ReNerve Limited (ASX:RNV) is transforming nerve repair and improving lives through breakthrough medical technology. Founded by a neurosurgeon and medtech researchers, ReNerve is a rapidly growing medical device company that has revolutionised peripheral nerve surgery with its innovative, ready-to-use solutions for peripheral nerve injuries (PNI). Our scientifically backed products are delivering measurably better outcomes for patients worldwide.

Proven Clinical Success

ReNerve's first flagship product, the FDA-cleared **NervAlign® Nerve Cuff**, is already making a dramatic difference in surgical outcomes across the United States. A recently announced clinical study has demonstrated remarkable results, showing that patients treated with the NervAlign® Nerve Cuff experienced post-surgical pain scores dropping from 7.1 to just 0.4, compared to from 7.1 to 3.3 without the device being used – a statistically significant improvement that's changing lives.

Comprehensive Product Portfolio

ReNerve is advancing a complete suite of nerve repair solutions:

- **NervAlign® Nerve Cuff** – Our bioabsorbable protective wrap, naturally absorbed within six months of surgery.
- **Deep Dermal tissue product** -- A unique deep dermal product used in the repair of reconstructive and cosmetic surgical cases.
- **Amniotic tissue product ranges** -- Three amniotic tissue product ranges used to aid the healing of wounds.
- **NervAlign® Nerve Conduit Range** – Next-generation nerve conduit leveraging advantages of eCOO technology in a material designed to facilitate nerve growth over short gaps between nerve ends.
- **NervAlign® Nerve Guide Matrix** – a customised and ready-to-use alternative to existing nerve grafts, for treatment of longer nerve gaps and more severe nerve injuries. It will eliminate the need for patients to undergo additional sural nerve harvesting.
- **NervAlign® Bionic Nerve** – Next-generation combination technology for the most challenging nerve repairs.

Market Leadership and Growth

With demonstrated market traction since the Company's 2022 product launch, ReNerve achieved 53% revenue growth in FY25, reaching \$271k in sales. Our high-margin, scalable products are positioning us as the go-to solution for surgeons seeking superior patient outcomes in the rapidly expanding global nerve repair market, valued at US\$1.6 billion in 2024 and is projected to reach \$6.2 billion by 2031.¹

¹ Global Nerve Repair Biomaterials Market Research Report (2020 – 2031)

Vision and Values

We're not just developing medical devices – we're engineering hope. By creating the ideal healing environment for nerve repair and regeneration, ReNerve bridges critical gaps in healthcare while empowering the human body's natural healing process. Our cleaner, safer, and more effective solutions represent the future of peripheral nerve surgery.